Kronos Bio Inc KRON Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.88 up $0.01, 1.49% at close Jun 20
Last close · Previous close $0.87
- Market cap
- At the Jun 20 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.07Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.88up $0.20, 30.35%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.87Jun 18
- Volume54.09KJun 20 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.35MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Jun 20 close. Total return includes reinvested dividends.Price change only, without dividends.
| Period | KRON |
|---|---|
| Short term | |
| 1M | KRON: up 30.4% |
| 3M | KRON: unchanged |
| YTD | KRON: down 7.4% |
| 1Y | KRON: down 15.4% |
| Long term | |
| 3Y | KRON: down 74.9% −36.9% a year |
$10,000 invested in KRON a year ago (Jun 20, 2024) would be worth about $8,462 at the close on , with dividends reinvested.
| Period | KRON |
|---|---|
| Short term | |
| 1M | KRON: up 30.4% |
| 3M | KRON: unchanged |
| YTD | KRON: down 7.4% |
| 1Y | KRON: down 15.4% |
| Long term | |
| 3Y | KRON: down 74.9% −36.9% a year |
$10,000 invested in KRON a year ago (Jun 20, 2024) would be worth about $8,462 at the close on , not counting dividends.
All-time high
$38.23
Closing high on . Now 97.7% below that record.
Split-adjusted daily closes since Oct 9, 2020.
Stock splits
KRON hasn’t split since its price history begins in 2020.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY25, the quarter ended Mar 31, 2025. “Last 12 months” means the four quarters from Apr 1, 2024 to Mar 31, 2025, and balance-sheet figures are as of Mar 31, 2025.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $9.19Mup 21.2%
- Net income
- −$64.49M
- Diluted EPS
- −$1.07
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY23 (Jun 30, 2023) | $1.86M | −$29.74M | −$0.52 |
| Q3 FY23 (Sep 30, 2023) | $917.00K | −$31.37M | −$0.54 |
| Q4 FY23 (Dec 31, 2023) | $2.29M | −$25.32M | −$0.43 |
| Q1 FY24 (Mar 31, 2024) | $2.52M | −$29.96M | −$0.50 |
| Q2 FY24 (Jun 30, 2024) | $2.69M | −$16.20M | −$0.27 |
| Q3 FY24 (Sep 30, 2024) | $2.37M | −$14.11M | −$0.23 |
| Q4 FY24 (Dec 31, 2024) | $2.27M | −$25.81M | −$0.43 |
| Q1 FY25 (Mar 31, 2025) | $1.86M | −$8.36M | −$0.14 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $0.00 | −$88.44M | −$5.43 |
| FY21 (Dec 31, 2021) | $0.00 | −$151.08M | −$2.76 |
| FY22 (Dec 31, 2022) | $0.00 | −$133.20M | −$2.37 |
| FY23 (Dec 31, 2023) | $6.29M | −$112.67M | −$1.95 |
| FY24 (Dec 31, 2024) | $9.85M | −$86.08M | −$1.43 |
Margins
- Gross 100.0%
- Operating −765.2%
- Net −701.5%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$54.38MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$54.38MLast 12 months
- Capital spending$3.00KLast 12 months
- −591.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $245.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $101.76MAs of Mar 31, 2025
Cash plus short- and long-term marketable securities on the Mar 31, 2025 balance sheet.
- Total debt$24.09MAs of Mar 31, 2025
- Net cash$77.67MAs of Mar 31, 2025
- 12.93As of Mar 31, 2025
Current assets divided by current liabilities on the Mar 31, 2025 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.30As of Mar 31, 2025
Total debt divided by shareholders’ equity on the Mar 31, 2025 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −64.2%Last 12 months
Over the last 12 months, Kronos Bio lost money: its net loss was 64.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −47.2%Last 12 months
Over the last 12 months, Kronos Bio’s net loss was 47.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Kronos Bio Inc
Kronos Bio is a biopharmaceutical company developing small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. Our proprietary discovery engine decodes complex transcription factor regulatory networks to identify druggable cofactors. We screen for and optimize small molecules that target these cofactors in a disease-specific context. Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
KRON news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
KRON stock FAQ
What is KRON stock’s price today?
Kronos Bio (KRON) traded at $0.88 at the close on , up $0.01 (1.49%) from the previous close of $0.87.
What is KRON’s P/E ratio?
KRON’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.07).
How much revenue does Kronos Bio make?
Kronos Bio reported $9.2 million of revenue over the four quarters to , up 21.2% from the twelve months before. In its latest quarter (Q1 FY25, ended ) revenue was $1.9 million, down 26.0% from a year earlier.
Is Kronos Bio profitable?
Not over the four quarters to . Kronos Bio reported a net loss of $64.5 million across those four quarters on $9.2 million of revenue.
What are KRON’s earnings per share?
KRON’s diluted earnings per share were −$1.07 over the four quarters to , compared with −$1.99 in the twelve months before. The latest quarter (Q1 FY25) brought −$0.14 per share, against −$0.50 a year earlier (how EPS works).
Does KRON pay a dividend?
Kronos Bio hasn’t paid a dividend in the last twelve months.
What is KRON’s all-time high?
KRON’s highest closing price was $38.23 on , adjusted for stock splits. At $0.88 at the close on , it is 97.7% below that record.
Has KRON stock ever split?
No. KRON hasn’t split since its price history begins in 2020.
How has KRON stock performed?
Including dividends and measured to the close on , KRON has returned −7.4% so far this year and −15.4% over the past year. Past performance doesn’t predict future returns.
What sector and industry is Kronos Bio in?
Kronos Bio is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does KRON trade on?
Kronos Bio trades on the Nasdaq under the ticker symbol KRON. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.